OncoMatch/Clinical Trials/NCT07469891
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Official title: A Phase 1, Open-Label, Multi-Center, Safety and Efficacy Study of PRT12396 in Participants With Polycythemia Vera and Myelofibrosis
Is NCT07469891 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies PRT12396 for polycythemia vera (pv).
Treatment: PRT12396 — This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Myeloproliferative Neoplasm
Biomarker criteria
Required: JAK2 v617 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy for PV or MF
Prior systemic therapy for PV or MF
Cannot have received: allogeneic hematopoietic stem-cell transplantation
Exception: planned transplantation
prior or planned allogeneic hematopoietic stem-cell transplantation
Cannot have received: splenectomy
prior splenectomy
Cannot have received: splenic irradiation
prior splenic irradiation
Lab requirements
Blood counts
Adequate bone marrow reserves (hematology) per protocol
Kidney function
Adequate renal function per protocol
Liver function
Adequate hepatic function per protocol
Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Colorado Blood Cancer Institute · Denver, Colorado
- BRCR Global - Coral Springs · Coral Springs, Florida
- Moffitt Cancer Center · Tampa, Florida
- START Midwest, LLC · Grand Rapids, Michigan
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07469891 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for PV or MF, allogeneic hematopoietic stem-cell transplantation, splenectomy disqualifies patients from enrollment.
Does this trial require JAK2?
Yes, JAK2 v617 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages